TGF-β and p53 staining in CT-guided and endoscopic ultrasound fine-needle aspirates of pancreatic adenocarcinoma

Digestive Diseases and Sciences

Volumn 49, Issue 5, 2004, Pages 828-832

  Sears, Dawn ^a   Erickson, Richard A ^a   Sayage Rabie, Lubna ^a   Escobar, Martha C ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

endoscopic ultrasound; p53; pancreatic cancer; transforming growth factor ; tumor markers

Indexed keywords

PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLOGY; DEMOGRAPHY; DISEASE MARKER; ENDOSCOPIC ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NEEDLE BIOPSY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; STAINING;

ADENOCARCINOMA; AGED; BIOPSY, FINE-NEEDLE; ENDOSONOGRAPHY; FEMALE; HUMANS; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; STAINING AND LABELING; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3042850196     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DDAS.0000030095.71501.04     Document Type: Article

References (33)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 48:6-29, 1998
2. Coppola D, Lu L, Fruehauf JP, Kyshtoobayeva A, Karl RC, Nicosia SV, Yeatman TS: Analysis of p53, p21 WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta protein expression predicts longer survival. Am J Clin Pathol 110:16-23, 1998
3. Campani D, Boggi U, Cecchetti D, Esposito I, Ceccarelli F, D'Antonio L, De Negri F, Mosca F, Bevilacqua G, Fornaciara G: p53 overexpression in lymph node metastases predicts clinical outcome in ductal pancreatic cancer. Pancreas 19:26-32, 1999
4. Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, McConkey DJ, Bucana CD, Clearly ICR, Hallin PA, Chiao PJ, Abbruzzese JL, Evans DB: Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg 3:263-277, 1999
5. Apple SK, Hecht JR, Lewin DN, Jahromi SA, Grody WW, Nieberg RK. Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic and carcinomatous lesions of the pancreas: Evidence for multistep carcinogenesis. Hum Pathol 30:123-129, 1999
6. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Kloppel G, Kalthoff H, Ungefroren H, Lohr M, Scarpa A: Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 439:798-802, 2001
7. Sun C, Yamato T, Furukawa T, Ohnishi Y, Kijima H, Horii A: Characterization of mutations of the K-ras, p53, p16 and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep 8:89-92, 2001
8. Nio Y, Dong M, Iguchi C, Yamasawa K, Toga T, Itakura M, Tamura K. Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: Effects on clinical outcome and efficiency of adjuvant chemotherapy. J Surg Oncol 76:188-196, 2001
9. Kawesha A, Ghaneh P, Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S, Evans JD, Campbell F, Lemione N, Neoptolemos JP: K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2, and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 89:469-474, 2000
10. Kawahira H, Kobatashi S, Kaneko K, Asano T, Ochiai T: p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy. Hepatogastroenterology 47:973-977, 2000
11. Cascallo M, Mercade E, Capella G, Lluis F, Filial C, Gomez-Foix AM, Mazo A: Genetic background determines the response to adenovirus-mediated wild type p53 expression in pancreatic tumor cells. Cancer Gene Ther 6:428-436, 1999
12. Ghaneh P, Greenhalf W, Humphreys M, Wilson D, Zumstein L, Lemoine NR, Neoptolemos JP: Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene The 8:199-208, 2001
13. Kusumoto M,Ogawa T, Mizumoto K, Ueno H, Niiyama H, Sato N, Nakamura M, Tanaka M: Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effects on cell cycle arrest and apoptosis in human pancreatic cancer cells. Clin Cancer Res 5:2140-2147, 1999
14. Ahmed MM, Alcock RA, Chendil D, Dey S, Das A, Venkatasubbarao K, Mohiuddin M, Sun L, Strodel WE, Freeman JW: Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2. J Biol Chem 277:2234-2246, 2002
15. Mercade E, Cascallo M, Carrio M, Calbo J, Gomez-Trevino A, Fillat C, Gomez-Foix AM, Mazo A: Treatment based on a combination of CYP2B1/ cyclophosphamide system and p53 delivery enhances tumour regression in human pancreatic cancer. Ann Oncol 12:379-388, 2001
16. Dong M, Nio Y, Tamura K, Song MM, Guo KJ, Guo RX, Dong YT: Ki-ras point mutation and p53 expression in human pancreatic cancer: A comparative study among Chinese, Japanese and Western patients. Cancer Epidemiol Biomark Prev 9:273-284, 2000
17. Yamaguchi Y, Watanabe H, Yrdiran S, Ohtsubo K, Motoo Y, Okai T, Sawabu N: Detection of mutations of p53 tumor suppressor gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: Comparison with K-ras mutation. Clin Cancer Res 5:1147-1153, 1999
18. Yamaguchi K, Chijiiwa K, Torato N, Kinoshita M, Tanaka M: Ki-ras codon 12 point and p53 mutations: A molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer. Am J Gastroenterol 95:1939-1945, 2000
19. Tomaszewska R, Karcz D, Stachura J: An immunohistochemical study of the expression of bcl-2 and p53 oncoproteins in pancreatic intraepithelial neoplastic and pancreatic cancer. Int J Pancreatol 26:163-171, 1999
20. Markowitz SD, Roberts AB, Lang SA, Kersting M, Baumann R, Wild A, Moll R, Rothmund M, Bartsch DK: Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 7:93-102, 1996
21. Gerdes B, Ramaswamy A, Ziegler A, Lang SA, Kersting M, Baumann R, Wild A, Moll R, Rothmund M, Bartsch DK: p16INK4a, is a prognostic marker in resected ductal pancreatic cancer: An analysis of p16INK4a, p53,MDM2, an Rb. Ann Surg 235:51-59, 2002
22. Jimenez RE, Warshaw AL, Zgraggen K, Hartwig W, Taylor DZ, Compton CC, Fernandez-del Castillo: Sequential accumulation of K-ras mutation and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg 230:501-509, 1999
23. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ: Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 86:886-892, 2002
24. Friess H, Kleeff J, Korc M, Buchler MW: Molecular aspects of pancreatic cancer and future perspectives. Dig Surg 16:281-290, 1999
25. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, Korc M: Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105:1846-1856, 1993
26. Giehl K, Seidel B, Gierschik P, Adler G, Menke A: TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation. Oncoge 19:4531-4541, 2000
27. Simeone DM, Pham T, Logsdon CD: Disruption of TGFbeta signaling pathways in human pancreatic cancer cells. Ann Surg 232:73-80, 2000
28. Kleeff J, Ishiwata T, Marayama H, Friess H, Truong P, Buchler MW, Falb D, Korc M: The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 18:5363-5372, 1999
29. Venkatasubbarao K, Ahmed MM, Mohiuddin M, Swiderski C, Lee E, Gower WR Jr, Salhab KF, McGrath P, Strodel W, Freeman JW: Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma. Anticancer Res 20:43-51, 2000
30. Wagner M, Kleeff J, Friess H, Buchler M, Korc M: Enhanced expression of the type II transforming growth factor b receptor is associated with decreased survival in human pancreatic cancer. Pancreas 19:370-376, 1999
31. Erickson RA, Sayage-Rabie L, Avots-Avotins A: Clinical utility of endoscopie ultrasound-guided fine needle aspiration. Acta Cytol 41:1647-1653, 1997
32. Erickson RA, Sayage-Rabie L, Beisner RS: Factors predicting the number of EUS-guided fine needle passes for diagnosis of pancreatic malignancies. Gastrointest Endosc 51:184-190, 2000
33. Andoh A, Shimada M, Takaya H, Hata K, Fujiyama Y, Bamba T: Transforming growth-factor beta1 acts as a potent inhibitor of complement C3 biosynthesis in human pancreatic cancer cell lines. Pancreas 20:138-145, 2000